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9244 | Chem. Sci., 2019, 10, 9244–925of anti-tumour platinum drugs
using DNA-coiling gold nanoparticles bearing
lumophores and intercalators: towards a new
generation of multimodal nanocarriers with
enhanced action†
Ana B. Caballero, ‡a Lucia Cardo, §a Sunil Claire,a James S. Craig, b
Nikolas J. Hodges,c Anton Vladyka,a Tim Albrecht,a Luke A. Rochford,a
Zoe Pikramenou*a and Michael J. Hannon *a
New gold and lipoic based nanocarriers for the delivery of platinum(II) and platinum(IV) drugs are developed,
which allow enhanced loading of the drug on the surface of the nanocarriers and release in a pH-dependent
fashion, with superior release at lower pHs which are associated with many tumours. The conjugate
nanoparticles and their conjugates enter cells rapidly (within 3 hours). They tend to cluster in vesicles
and are also observed by light and electron microscopies in the cytoplasm, endoplasmic reticulum and
nucleus. We further incorporate aminoanthraquinone units that are both ﬂuorophores and DNA
intercalators. This results in nanocarriers that after drug release will remain surface decorated with DNA-
binders challenging the conventional design of the nanocarrier as an inert component. The outcome is
nanocarriers that themselves have distinctive, remarkable and unusual DNA binding properties being able
to bind and wrap DNA (despite their anionic charge) and provide enhanced cytotoxic activity beyond
that conferred by the platinum agents they release. DNA coiling is usually associated with polycations
which can disrupt cell membranes; anionic nanoparticles that can cause novel and dramatic eﬀects on
DNA may have fascinating potential for new approaches to in-cell nucleic acid recognition. Our ﬁndings
have implications for the understanding and interpretation of the biological activities of nanoparticles
used to deliver other DNA-binding drugs including clinical drug doxorubicin and its formulations.Introduction
The use of nanocarriers has attracted much recent interest for
improving delivery of drugs toward specic biological targets to
achieve safer and more eﬀective therapy.1–5 The conjugation of
a drug to a nanovehicle might also prevent its deactivation byham, Edgbaston, Birmingham B15 2TT,
ramenou@bham.ac.uk
niversity of Birmingham, Edgbaston,
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TEM cell uptake data. See DOI:
ganic and Organic Chemistry (Sect.
celona, Mart´ı i Franque`s 1-11, 08028
nology Lab, CIC biomaGUNE Parque
n 182, 20014 Donostia-San Sebastia´n,
6other biomolecules and enhance its bioavailability and stability.
Smart designs can be further employed to control drug release
kinetics by internal or external stimuli and bypass standard
multidrug resistance mechanisms by opening up alternative
uptake processes.1,6–11
Cisplatin, and ve other similar designs of platinum
compounds, are crucial clinical drugs for many cancer treat-
ments, with cisplatin, carboplatin and oxaliplatin licensed
worldwide and used to treat many patients each year.12–16
Despite their great eﬃcacy, the use of platinum drugs is limited
by severe toxic eﬀects, problems in bioavailability and acquired
resistance, among other factors. Toxicity of current platinum
drugs is in part due to their lack of specicity towards cancer
cells. This is aggravated by relatively high doses of drug needed
to be eﬀective, since these compounds oen suﬀer inactivation
by diverse biomolecules present in the organism, such as
glutathione and metallothionein, and only a tiny fraction rea-
ches their target, DNA.17,18
As such, platinum drugs are strong candidates for nano-
carrier delivery and a variety of diﬀerent types of nanocarriers
have been explored: many of them have made signicantThis journal is © The Royal Society of Chemistry 2019
Fig. 1 GNP-lip and ﬂuorescently labelled GNP-lip-AA nanocarriers for
platinum drug delivery.
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View Article Onlineprogress in terms of solubility, cell uptake and eﬃcacy and
some nano-formulations have entered clinical trials, but none
have yet been approved.5,19–24
Gold nanoparticles (GNPs) have been shown to be versatile
drug-delivery platforms for diﬀerent drugs, allowing easy
conjugation procedures and the possibility of co-loading
diﬀerent functionalizing units, such as targeting vectors or
imaging probes to modify and control biodistribution.4,25–29 In
addition, GNPs are themselves biocompatible, non-toxic and
inert; their size and dispersity is easy to control and small GNPs
eﬃciently penetrate cell membranes and can be monitored
inside cells using a variety of modalities.30–32 Anionic nano-
particles are perceived to be advantageous for drug delivery, as
cationic nanoparticles can disrupt membranes in the cell.33,34
A few studies exploring the potential of GNP-assisted delivery
of platinum drugs have been reported: carboxylate-
functionalized GNPs have been synthesized to conjugate
cisplatin35–40 and oxaliplatin41 by direct binding of Pt(II) to
carboxylic groups; cisplatin has also been attached to GNPs by
interaction with PEG chains42 and lipidic coatings forming two
or three layers;43 Pt(IV) prodrugs have been attached to GNPs
surface either by amide bonds through their labile axial
ligands,44 and non-covalently onto a GNP surface through
cyclodextrins (guest–host chemistry).45 Some of these examples
have employed release triggering mechanisms using pH-
sensitive carboxylate linkages39,40,46 and thiol groups.42
The current paradigm is that the nanocarrier is normally
designed as an inert component, with a role just to deliver and
release the drug. Yet the potential of these nanosystems is much
greater. Herein we challenge this paradigm through design of
a novel GNP-based nanocarrier that not only enables high drug
loading and subsequent release of platinum drugs in cells
(thereby enhancing their activity), but that also bears organic
units that are both uorophores and DNA intercalators. The
result is nanocarriers that are not inert but themselves have
remarkable DNA binding properties being able to bind and
wrap DNA, providing enhanced cytotoxic activity beyond that
conferred by the platinum agents they release.
Results and discussion
Molecular design
We designed a GNP-based platform, the two systems reported in
Fig. 1, GNP-lip and GNP-lip-AA, both functionalized with a-
lipoic acid (a molecule produced and present naturally in the
body) as coating material able to provide high stability and
biocompatibility to the carriers;47 the anionic lipoic unit is
a shorter linker compared to other carboxylic acid based linkers
employed in previous works,35–41 but still able to form pH-
sensitive bonds with platinum drugs and stabilize the systems
enough to allow post-functionalization with positively charged
moieties. GNP-lip-AA introduces the DNA-intercalating uores-
cent aminoanthraquinone (AA) anchored to the nanoparticle as
second functionality. AA was anchored to GNP by a thiolated
ethylene glycol linker, whose length was selected to avoid steric
hindrance eﬀects that might aﬀect the DNA-intercalation
properties.This journal is © The Royal Society of Chemistry 2019GNP-lip and GNP-lip-AA were then employed as carriers of
both cisplatin (PtII) and the Pt(IV) prodrug, c,c,t-[Pt(NH3)2-
Cl2(OH)(Hsuc)] (PtIVsuc), where Hsuc is the mono-
hydrogensuccinate anion.44 A feature of the design approach is
that the platinum centres are coordinated directly to the lipoic
surface of the nanoparticle, rather than using a pre-formed Pt
drug-linker system to attach to the gold below the surface layer.
Nanocarrier synthesis and characterization
The GNP-lip carrier was synthesized by coating citrate gold
nanoparticles with a-lipoic acid. GNP-lip-AA was then prepared
by adding the AA ligand (where the aminoanthraquinone is
previously functionalized with the ethylene glycol linker) to the
GNP-lip system (Fig. 1, S1 and S2†). Due to the negatively-
charged surface of both carriers, all functionalization steps
were carried out in basic media (pH > 10). Pre-coating of GNP
with anionic lipoate (to form GNP-lip) is essential to prevent
particle aggregation as observed when we attempted to func-
tionalize citrate GNP directly with AA.
Because of the ‘double thiol anchoring’ of lipoic acid to
GNPs, the displacement of this ligand is slower compared to
mono-thiolated ligands and a high excess of the secondary
ligand AA and long reaction times (18 h) were required to form
stable mixed-ligand particles GNP-lip-AA.
Binding of AA to GNP-lip was conrmed by a red shi in the
surface plasmon resonance (SPR) band in the UV-vis spectrum
(Fig. S2†). FT-IR spectra also conrmed the presence of both
lipoate and AA ligands (from their ngerprints) with the loss of
the S–H bond stretching band of both ligands, conrming
attachment to gold surface via this group (Fig. S3†).
To be suitable for conjugation to the carboxylate group of the
lipoic linker, the chloride ligands of both cisplatin and Pt(IV)
prodrug c,c,t-[Pt(NH3)2Cl2(OH)(O2CCH2CH2CO2H)], were
removed by precipitation with Ag(I), achieving the activated
aquo analogues (Scheme 1). Again, because GNP-lip and GNP-
lip-AA are negatively-charged systems, the attachment of plat-
inum drugs was carried out in basic conditions (pH 10), where
the rate of platinum binding to GNPs would be controlled by an
equilibrium with the formation of less-labile hydroxyl-
complexes;12 this facilitates a homogeneous binding processChem. Sci., 2019, 10, 9244–9256 | 9245
Scheme 1 Activation of platinum drugs and attachment onto the GNP
surface via the carboxylate group of lipoic acid linkers.
Fig. 2 Loading of Pt complexes onto GNP-lip and GNP-lip-AA,
measured by ICP-MS analysis. Results are the average of at least four
replicates (SD).
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View Article Onlinewhile avoiding particle collapse by a total charge neutralization.
The S of the lipoic acid is (strongly) bound to the Au of the
nanoparticle and the exterior of the nanoparticle presents
a surface array of carboxylates as evidenced by the zeta
potential.
Characterization of the synthesized GNP conjugates was
performed by TEM, DLS, UV-vis and uorescence studies, and
in part summarized in Table 1 (see also S4–S8); the cores of both
the GNP-lip and GNP-lip-AA-based systems are ca. 14 nm in size
with low polydispersity (see also Fig. S4†). The red shi in the
UV-vis band (Fig. S5†) is indicative of the change of the surface
of the nanoparticle indicating the attachment of the platinum
complex.
All GNP-lip-AA particles, with and without attached platinum
drugs, showed analogous emission bands centred at 645 nm
upon excitation at 470 nm (Fig. S8†) in water, attributed to the
presence of aminoanthraquinone.48
The average drug loading onto GNP-lip and GNP-lip-AA
conjugates was determined by calculating the number of PtTable 1 Characterization of the nanocarriers before and after attaching
GNP-lip
Hydrodynamic diameter (nm; from DLS) 10  4
Core diameter (nm; from TEM) 14  3
z-potential (mV) 44  19
SPR band (nm) 522
GNP-lip-AA
Hydrodynamic diameter (nm; from DLS) 23  7
Core diameter (nm; from TEM) 14  3
z-potential (mV) 38  6
SPR band (nm) 528
9246 | Chem. Sci., 2019, 10, 9244–9256atoms per GNP, obtained by measuring the concentration of Pt
and Au by ICP-MS (Fig. 2). The amount of platinum per GNP,
detected in each conjugated system, reects the platinum drug/
GNPmolar ratio employed for their syntheses (see Experimental
details), and the loading of Pt(II)-drug is higher compared to
Pt(IV)-drug, consistent with the diﬀerent reactivity of the two
oxidation states. The GNP-lip-AA particles are expected to bear
less lipoic sites and the loading is consequently lower. Never-
theless, in all cases, this synthetic strategy, based on pre-coating
the GNP with the coordinating linker (lipoate) rst, followed by
the anchoring of the Pt-drug, yielded signicantly higher
loading of the drug, than other reported GNP conjugates, in
which a pre-formed Pt drug-linker system is attached to parti-
cle.{ Probably, nanoparticle pre-coated with the linker presents
a higher density of charged anchoring sites on the surface,
which helps improving both particle stability and nal drug
distribution.In vitro stability
Since these Pt-drug-nanocarrier conjugates were developed to
explore their activity in cells, their stability in cell culture media
was investigated. Puried suspensions of Pt-containing and
non-Pt containing conjugates were centrifuged at 5000g forPtII and PtIVsuc complexes onto their surface
GNP-lip-PtII GNP-lip-PtIVsuc
15  5 15  5
14  3 15  3
39  6 43  8
525 525
GNP-lip-AA-PtII GNP-lip-AA-PtIVsuc
25  7 25  7
15  4 15  4
34  6 37  11
530 530
This journal is © The Royal Society of Chemistry 2019
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View Article Online30 min and the pellets further dispersed in serum-
supplemented cell media (RPMI 1640 and DMEM).
UV-Vis spectra and hydrodynamic size determinations were
collected at diﬀerent times (Fig. S9–S10†), showing only minor
particle aggregation in cell media over 72 hours. Overall, all
colloidal suspension remained stable over the time monitored.
According to Liu et al.,48 certain levels of aggregation would be
an advantage for our purposes: nanoparticles with a diameter
between 30 and 200 nm can accumulate more eﬀectively inside
tumour tissues and therefore retention and cellular uptake of
small nanoparticles (<30 nm) can be enhanced by stimulated
aggregation of nanoparticles. This also aids their visualization
by confocal microscopy, which was used to assess their cell
uptake (below).Fig. 3 Cumulative platinum drug release from GNP-lip and GNP-lip-
AA at pH 4.4 and at pH 7.4 (values and errors are presented as themean
and SD respectively from at least three independent experiments).In vitro drug release
We investigated drug release proles of the four Pt-containing
conjugates (GNP-lip-PtII, GNP-lip-PtIVsuc, GNP-lip-AA-PtII and
GNP-lip-AA-PtIVsuc) in diﬀerent conditions by measuring
concentrations of Pt and Au with ICP-MS.
First, we analysed drug release at diﬀerent times, in cell
media (RPMI and DMEM), in an incubator at 37 C (same
conditions employed for in cellulo studies, described below).
The highest percentage of release occurs within the rst 5 hours
of incubation: 20% of PtII drug is released fromGNP-lip and 40–
50% from GNP-lip-AA, while for the analogous PtIVsuc conju-
gates,50% of the platinum is released from both nanosystems
(Fig. S11†).
It should be noted that cell media contains several Pt-
binding species at relatively high concentrations, such as L-
lysine (40 and 146 mg L1 in RPMI and DMEM), L-cystine (50
and 63 mg L1 in RPMI and DMEM), or reduced glutathione
(1 mg L1 in RPMI); an equilibrium between diﬀerent Pt-
containing systems can be reached during the rst 5 h (ref.
49) and these would obviously aﬀect Pt-drug release prole.
According with our initial hypothesis, the designed nano-
carriers GNP-lip and GNP-lip-AA should also be able to release
the platinum drugs in a pH-controlled fashion; therefore, we
determined and compared the percentage of drug that is
released at (a) pH 7.4 (in phosphate buﬀered saline, mimicking
cellular pH) and (b) pH 4.4 (in phthalate–NaOH buﬀer,
mimicking endosomal environment), which are higher and
lower than carboxylic acid pKa, respectively.
The percentage of drug released from each system was
measured aer 3 h and 24 h of incubation in buﬀer at room
temperature. As shown in Fig. 3, in all cases drug release is
signicantly higher at pH 4.4 than pH 7.4. There are no major
diﬀerences between GNP-lip and GNP-lip-AA in terms of release
(indicating that the AA does not interfere with the Pt release)
whilst in all the conditions explored, there is a higher release of
PtIVsuc than PtII, suggesting a weaker binding to GNP; we
speculate that a fraction of PtIVsuc molecules might not have
formed coordination bonds with GNP surface carboxylate
groups, and instead, could be attached solely by electrostatic
interactions, with ionic strength changes eﬀecting release.This journal is © The Royal Society of Chemistry 2019In all cases, drug release in buﬀer at pH 7.4 is lower
compared to release in media with similar pH (Fig. S11†),
indicating that the potential Pt-binders contained in media
(serum proteins, amino acids etc.) might play a role in facili-
tating the release of the drug (potentially coordinated in place of
the carboxy groups that held the drug on the nanoparticle).Drug activity: cytotoxicity assays
The toxicity of the new nanocarrier-Pt drug conjugates was
tested in the A549 human lung cancer and A2780 human
ovarian cancer cell lines by MTT assay, and compared with the
cytotoxicity of free drugs and nanocarriers before drug loading.
Results are summarized in Table 2, where IC50 values of all
nanoparticle-based compounds refers to the concentrations of
GNP (nM). We also calculated the concentration (mM) of Pt-drug
theoretically carried by the nanocarrier at each IC50 point (using
the drug loading studies reported in Fig. 2). This allows an
approximate comparison of the activities of the conjugated and
free drugs (although it does not account for any unreleased
platinum that remains attached to the GNP).
For the GNP-lip carrier, in the case of the Pt(II) conjugates the
IC50 values are similar to those of cisplatin alone (see ESI Table
1† for statistical analysis). However delivery of Pt(IV) drug using
GNP-lip system does enhance the activity of the drug as
concentration of the drug carried at IC50 points is 2 and 4 fold
lower (in A2780 and A549 respectively) compared to IC50 values
of the free drug; this is likely due to a combination of the drug
amplication eﬀect (typical for drug delivered by nanocarriers)
and the higher drug release of this system (compared to the
Pt(II) release, see Fig. 3 and S11†).
Our experiments in these cell lines do reveal a certain level of
toxicity for GNP-lip systems even though such nanoparticlesChem. Sci., 2019, 10, 9244–9256 | 9247
Table 2 Cytotoxicity of the non-Pt and Pt-containing conjugates compared with free platinum drugs (72 h incubation). IC50 values (nM,
concentration of compound needed to inhibit cell viability by 50%) of all GNP based systems refers to the concentration of nanoparticle; the
corresponding concentration of Pt-drug carried by each GNP system at the corresponding IC50 point (*) is also reported (values and errors are
presented as the mean and SD respectively from at least three independent experiments)
Compound
A2780 A549
IC50 (nM) Pt
a (mM) IC50 (nM) Pt
a (mM)
Cisplatin 1400  900 6000  2200
CisPtIVsuc-Cl 12100  3700 33000  12000
GNP-lip 17.1  3.7 41.6  3.5
GNP-lip-PtII 2.0  0.5 4.0  0.9 9.4  0.6 18.8  1.3
GNP-lip-PtIVsuc 4.0  0.1 6.3  0.1 5.5  0.3 8.6  0.5
GNP-lip-AA 2.6  1.8 1.7  0.7
GNP-lip-AA-PtII 1.6  0.6 1.9  0.9 1.6  0.7 2.0  0.9
GNP-lip-AA-PtIVsuc 2.3  0.5 1.8  0.4 1.0  0.7 0.8  0.7
a Concentration of Pt-drug (mM) potentially carried by the GNP at IC50 concentration.
Fig. 4 Confocal microscopy images of A549 alone (control A) and
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View Article Onlinehave recently been described as non-toxic in diﬀerent biological
systems and at lower incubation times.49 Nevertheless, the
toxicity of each of the drug conjugates is higher than that of the
carriers alone. The design oﬀers potential to but does not yet
include additional targeting vectors for specic cells or
tissues,4,25–29 but would potentially benet from gold nano-
particle enhanced permeability and retention in vivo.
As envisaged in our design, the GNP-lip-AA nanocarrier
showed a higher toxicity compared to the non AA-containing
system, GNP-lip; anti-proliferative activities of several amino-
anthraquinone derivatives has been described and they can
work as DNA intercalators or groove/backbone binders and/or
are able to generate reactive oxygen species upon visible light
illumination (although it should be noted that cells were incu-
bated in the dark).50,51 Indeed, the presence of AA on these
nanocarriers does aﬀect binding to DNA (DNA binding studies
were performed and discussed below). The GNP-lip-AA species
seem to have particularly good activity. The interpretation of the
data for the conjugates is complicated by the plethora of species
that will potentially be present and active (partially unloaded
GNP-lip-AA-Pt species as well as released platinum drug;
possibly also some fully unloaded GNP-lip-AA) but it is clear that
both the Pt(II) and Pt(IV) conjugates have high activity while no
statistically signicant advantage over the activity of the GNP-
lip-AA carrier itself is detected. Hambley has reported a mono-
nuclear cisplatin linked to an anthraquinone and similarly
noted being unable to statistically distinguish the cytotoxicity
from that of the anthraquinone.52,53 We will return to consider
this activity aer rst exploring the uptake and localisation of
these nanoparticles inside the cells.treated with diﬀerent nanocarrier conjugates (B to E) for 24 h, followed
by nuclei staining with Hoechst 33258 and ﬁxation. Each image (A to E)
shows (i) on the left, merged ﬂuorescent images of nuclei stained by
Hoechst 33258 (cyan) and AA (red, present only in (D and E), indicated
by yellow arrows), obtained upon excitation at 405 and 488 nm
respectively; (ii) on the right, the corresponding transmission images,
where GNPs appear as black dots. In (F), one example of orthogonal
view, upon compiled from a Z-stack of ﬂuorescent images (Hoechst
overlayed with AA channel) to conﬁrm that AA ﬂuorescence is inside
the cell at the perinuclear region.Nanoparticle uptake in cells: confocal microscopy
Confocal laser scanning microscopy (uorescence, reection
and transmission microscopy) was employed to visualize the
nano-conjugates inside cells. Non-uorescent GNP-lip particles
could be imaged only by transmission (brighteld mode) and
reection, whilst uorescent signals of AA-containing particles
could be detected using excitation at 488 nm. Since particles are9248 | Chem. Sci., 2019, 10, 9244–9256about 15 nm in size, it should be noted that only particles
forming aggregates inside the cells will be resolved and there-
fore visualized by the reectance technique.54
A459 and A2780 cells were treated with each compound for 3
and 24 hours, followed by nuclear staining with Hoechst 33258
(cyan) and xation. Representative examples of uorescent and
transmission images are reported in Fig. 4 and further images
are presented in Fig. S12–S37† showing early uptake (from 3 h).
Overall, we observed cellular uptake of all nanocarriers,
particularly evident as black dots in transmission images. TheThis journal is © The Royal Society of Chemistry 2019
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View Article Onlineuptake at the 24 hour time point is signicantly higher although
particles were present in cells already aer 3 hours. No diﬀer-
ences were observed between the two cell types nor when
varying GNP types (either loaded or not with drugs), suggesting
that the loaded drug does not aﬀect the cellular uptake of the
system. No changes in cell morphology or disruption to the
nucleus were evident (Fig. 4).
All GNPs were located mainly in the cytoplasm and in the
perinuclear region, rather than penetrating into the nucleus,
suggesting that their cytotoxic activity is either due to drugs
being released and/or a diﬀerent type of action occurring into
the cytoplasm. It must be noted however, that single/non-
clustered nanoparticles would not be visible, therefore their
presence in other parts of the cell (i.e. nucleus) is not excluded.
Z-stack images were recorded and orthogonal views conrm
that particles were indeed located inside (and not just on the
surface of) cells (Fig. 4F and S14–S37†). For all AA-containing
GNPs, signals corresponding to AA were evident in all images,
oen in the perinuclear area, however signal intensity was
rather modest (i.e. red dots in Fig. 4D, E and F) and may be
attributed only to where nanoparticles have accumulated/
clustered suﬃciently.Fig. 5 TEM images of A549 treated with (A) GNP-lip, (B) GNP-lip-AA,
(C) GNP-lip-PtII, and (D) GNP-lip-AA-PtIVsuc for 24 hours (N: nucleus,
NM: nuclear membrane, CM: cell membrane, V: vesicles, M: mito-
chondria). Magniﬁcations of red-dashed inset boxes are presented inNanoparticle uptake: transmission electron microscopy
To ascertain the intracellular localization of the nano-
conjugates, A549 and A2780 cells were treated for 24 h with the
nanoparticles and then imaged by TEM. Inside the cells most
particles were found to accumulate in endosomal vesicles in the
perinuclear region (representative examples in Fig. 5 and
further images in S38–S44). One possible mechanism of delivery
is via a vesicular intermediate directly from the plasma
membrane. Some micrographs also show a few particles freely
dispersed in the cytosol, in the endoplasmic reticulum and
inside the nucleus. This implies that these nanocarriers can
circumvent, or escape from, the endosomal pathway and end up
in the nucleus without the need for specic functionalization,
such as addition of membrane penetrating peptides.54
In such cases a fraction of platinum drug would potentially
be delivered into the nucleus attached to the GNP, while the
remainder would be released in the cytosol and make its way
freely towards the nucleus. In all cases, the particles show signs
of clustering when they are inside to the endosomes, consistent
with the confocal images where only aggregates could be
detected. In general, a higher vacuolization was observed,
compared to non-treated cells, and even nuclear disintegration
when A2780 cells were treated with GNP-lip-AA (Fig. S42†).the images labelled with corresponding asterisks.Interaction of GNP-lip-based nanocarriers with ct-DNA
Given the higher cytotoxic activity of GNP-lip-AA (compared to
the AA-free nanocarrier GNP-lip) and the observation of the
nanoparticle penetration into the nucleus, to better understand
the nanocarrier eﬀect, we compared the binding properties of
the two unconjugated nanocarriers to calf thymus (ct) DNA by
ow linear dichroism (LD), circular dichroism (CD) and
Dynamic Light Scattering (DLS) studies.This journal is © The Royal Society of Chemistry 2019All experiments were performed in NaCl (10 mM) and Tris–
HCl (1 mM, pH 7.5) buﬀer; no particle aggregation and/or ct-
DNA precipitation was observed in these conditions (controls
by UV-vis in Fig. S45†). The LD signal of ct-DNA (negative band
at 260 nm) decreases upon addition of increasing concentration
of the free aminoanthraquinone derivative AA (Fig. 6A) as would
be expected; this is typically observed when DNA stiﬀening isChem. Sci., 2019, 10, 9244–9256 | 9249
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View Article Onlinecaused by the presence of intercalative agents. GNP-lip alone
does not aﬀect DNA orientation in ow (Fig. 6B) whilst GNP-lip-
AA causes an increase of LD signal. Such an increase is typically
observed with coiling and/or bending of DNA which causes
a reduction in the linear orientation of the DNA in the ow (and
thus a signal reduction).72 These results indicate that presence
of AA is necessary to achieve binding between the nanocarrier
and DNA. Since the free AA binds by intercalation and that
intercalating part of the AA can project away from the nano-
particle surface and towards solution, it seems likely that the
presence of multiple intercalating units anchored on singleFig. 6 Linear dichroism spectra of ct-DNA (75 mM in Tris–HCl 1 mM
and NaCl 10 mM, pH 7.5) titrated with AA (A) GNP-lip (B) and GNP-lip-
AA (C). Legends show ct-DNA : AA ratio in (A) and ﬁnal concentration
of nanocarriers in (B) and (C).
9250 | Chem. Sci., 2019, 10, 9244–9256nanoparticles is resulting in a ‘DNA wrapping’ eﬀect around the
nanoparticle. The length of ct-DNA implies this condensation
might involve more than one nanoparticle per DNA. The
binding and coiling eﬀects are remarkable since both DNA and
the GNP-lip-AA are negatively charged. There is precedent for
condensation of DNA by cationic polymers and nanoparticles
(and indeed this is used in gene delivery systems) but this is
through electrostatic attraction, with backbone charge
compensation facilitating the DNA bending.
Titrations of ct-DNA vs. GNPs were performed also by
circular dichroism (CD); the spectra collected conrmed that
the GNPs cause no signicant perturbation of B-DNA structure
(i.e. a basic DNA structure is retained in the DNA coiled around
the GNP-lip-AA). No induced CD signals in the GNP spectros-
copies were observed (data not shown).
To provide conrmation of the interpretation of the LD
results, we further studied the interactions between ct-DNA and
the GNPs by DLS. Histograms in Fig. 7 report the percentage of
species present in one sample (expressed in relative intensity
distribution) with specic sizes (diameter in nm). ct-DNA alone
(blue lines) shows a unimodal peak centered at 250 nm, whilst
peaks corresponding to GNP-lip or GNP-lip-AA alone (black
dashed lines in Fig. 7A and B respectively) are centered around
19 nm.Fig. 7 DLS histograms showing the relative size distribution of ct-DNA
(11 mM, in Tris–HCl 1 mM and NaCl 10 mM), with an increasing
concentration of (A) GNP-lip and (B) GNP-lip-AA. Controls corre-
sponding to ct-DNA alone and GNPs alone are in both graphs as blue
solid and black dashed lines respectively.
This journal is © The Royal Society of Chemistry 2019
Fig. 8 AFM images of linearised pBR322 plasmid -DNA, (top) alone
and (bottom) with 2 equivalents of GNP-lip-AA. 2D images are
included in Fig. S46.†
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View Article OnlineSamples containing ct-DNA and GNP-lip (Fig. 7A) produce
two signals corresponding to separate GNP (18 nm; unchanged
by concentration) and DNA species (250 nm). The DNA species
are slightly shied between concentrations but there is no
evidence of new species with diﬀerent sizes suggesting that no
signicant changes in DNA conformation and/or GNP-lip
aggregation, and/or binding between the species, occurs.
Conversely, addition of GNP-lip-AA to the DNA (Fig. 7B)
causes the loss of the DNA signal around 250 nm and appear-
ance of a distinct bi-modal size distribution signal, which
includes (i) a peak at 24 nm, that remains at diﬀerent concen-
trations of GNP and (ii) a larger peak that shis from 108 nm to
93 nm to 84 nmwith increasing concentration of GNP. The peak
at 24 nm could either correspond to a new GNP-DNA adduct or
to GNP-lip-AA alone, size-shied because of the diﬀerent ionic
strength of the system. The size of the larger species decreases
when more GNP-lip-AA is added and would therefore corre-
spond to increased coiling/wrapping of the DNA as more GNP-
lip-AA is added and binds: this is consistent with, and rein-
forces, the observations from LD studies (Fig. 6C). Of the two
nanoparticles types, only GNP-lip-AA displays binding and
coiling activity toward DNA and it seems reasonable to
hypothesise that this may be related to its higher cytotoxicity.
We have also explored the coiling/wrapping using AFM
imaging. In contrast to the LD and DLS solution techniques,
AFM requires surface immobilisation; it was challenging to nd
a suitable surface coating that gave artefact free results. APTES
(an amine-based surface popular for DNA and nanoparticle
imaging) allowed deposition but in our hands, showed some
tendency to promote DNA condensation in absence of nano-
particles. However using nickel coated mica, we were able to
image linearised plasmid pBR322 (4361bp) alone and with two
equivalents of GNP-lip-AA. As shown in Fig. 8, the DNA does
indeed wrap about the nanoparticles. In the centre of the image
a partially wrapped-up DNA is observed, with two nanoparticles
observed wrapped within this DNA at one end and the other end
of the DNA owing out from the particles. The width and shape
of the nanoparticles clearly conrms that DNA is wrapped about
them. The broadening at the base of the structures is likely
a consequence of the surface deposition rather than an indi-
cation of some asymmetry in the wrapping in solution. While
the solution techniques alone are compelling evidence of the
wrapping of the DNA around these anionic nanoparticles, the
AFM provides further evidence for this remarkable binding and
DNA wrapping.
Cationic nanoparticles are known DNA condensation
agents55 driven by strong electrostatic attraction to the DNA
polyanion, however anionic nanoparticles will not benet from
such strong electrostatic interaction energy (unless under high
salt conditions where salt cations might shield the anionic
repulsion). Nevertheless, in intriguing early studies, Murphy56
and A˚kerman57 reported some form of interaction between ds-
DNA and citrate coated gold nanoparticles and there have
been some subsequent similar reports.33,58,73–75 The interaction
is weak and its nature unclear, with suggestions including
direct adsorption to the gold with displacement of the citrate.56
This does demonstrate that anionic charge on the surface of theThis journal is © The Royal Society of Chemistry 2019nanoparticle does not exclude DNA-binding as long as there are
suﬃcient favourable interactions to counter it; on a macromol-
ecule such as a nanoparticle this may be possible. However,
such ds-DNA binding is not replicated by our anionic lipoic
GNP-lip particles (without the AAs) under the conditions of our
studies; no indication of a signicant DNA interaction is
observed (by CD, LD or DLS). The binding of the AA function-
alised nanoparticles (GNP-lip-AA) to DNA is thus not simply an
inherent property of lipoic coated gold nanoparticles, but
a consequence of the AA groups on the surface.
The most common examples of intercalators on gold nano-
particles are the many reports of doxorubicin functionalised gold
nanoparticles, inspired by the doxorubicin liposomal formula-
tions that are enjoying success in the clinic.59–64 Yet these designs
are all focused on using cleavable linkers to attach to the nano-
particle surface so as to facilitate release of the doxorubicin; the
DNA-binding of these particles themselves has not been explored.
In just a few reports intercalators have been attached to gold
nanoparticles for example to detect DNA in assays: Murray
attached low loadings of ethidium bromide (1–2 per nano-
particle) to cationic and anionic gold nanoparticles through a C12
chain thiol.65 The cationic nanoparticles bound rapidly, but the
anionic ones only slowly and in high salt suggesting the binding
was salt assisted. Subsequent work has attached acridine orange
through alkylthiol chains onto neutral PEG coated gold nano-
particles or via attachment to a chitosan polymer, and psoralen
via a high-molecular-weight aminodextran polymer.66–68 All bind
DNA, but the designs are each distinct from that herein, and none
of these reports explored or noted DNA coiling eﬀects.Chem. Sci., 2019, 10, 9244–9256 | 9251
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View Article OnlineOur ndings have implications for the interpretation of the
activities of designs used for GNP (and indeed other nano-
particle) delivery of doxorubicin. Many of these nanoparticle
delivery systems report enhanced doxorubicin activity. The
assumption has been that the increased activity is due to better
target delivery of active doxorubicin released from its nano-
carrier, and release of large payloads in the same vicinity. Yet
when using cleavable linkers, a range of species is possible in
solution, including not only the free doxorubicin, but nano-
particles with varying numbers of residual doxorubicins. The
work herein, indicates that such nanoparticles can bind DNA in
new ways diﬀerent from the individual drug, and can cause
distinct and potent eﬀects. If nanoparticles bearing residual (un-
cleaved) doxorubicins penetrate the nucleus or mitochondria to
encounter cellular DNA, or encounter RNA elsewhere in the cell,
they could be acting as non-innocent species adding enhanced
toxicity beyond that of the released drug itself. This brings an
intriguing new dimension to how we could consider such agents.Experimental details
All gold nanoparticle suspensions were stored in darkness at
4 C and ltered (glass bre syringe lter 1 mm) before being
used/characterized. Deionised water was used in all syntheses.
14 nm citrate gold nanoparticles were prepared according to
previously reported protocols.69
1H NMR and 13C NMR spectra were recorded on ACIII-300
(300 MHz) and AVIII-400 Bruker spectrometers (400 MHz),
respectively. Chemical shis were referenced to tetramethylsi-
lane or H2PtCl6 as an internal standard or to residual solvent
peaks. Electrospray ionization (ESI) mass spectra were recorded
on a Micromass LCT ToC mass spectrometer in a positive ion-
isation mode. FT-IR spectra were recorded on a Nicolet Avatar
320 spectrophotometer with an ATR attachment. UV-vis anal-
yses were carried out at room temperature in a Varian Cary 5000
UV-vis spectrophotometer using 10 mm cuvettes. The hydro-
dynamic diameter and surface charge (z-potential) of the
nanoparticles were measured using a Zetasizer Nano ZS (Mal-
vern Instruments Ltd, Malvern, UK). Measurements were per-
formed (12 cycles per run) in triplicate. The value for the
hydrodynamic diameter of the particles was obtained using the
number scaling.
Fresh Pt-functionalized samples were used for each
measurement and cell experiment. Each spectroscopic (UV-vis,
LD, DLS) experiment was repeated at least twice to conrm
reproducibility.
All reported uncertainties represent one standard deviation
calculated from at least three replicate measurements.Synthesis of platinum drugs
Cisplatin was purchased from Alfa Aesar and used without
further purication. The Pt(IV) complex c,c,t-[Pt(NH3)2-
Cl2(OH)(O2CCH2CH2CO2H)] (PtIVsuc-Cl) was prepared as
previously described.44 Aerwards chloride ions from both
complexes were removed by adding AgNO3 to form AgCl
precipitate. The solutions were ltered (0.45 mm lter) and then9252 | Chem. Sci., 2019, 10, 9244–9256centrifuged to remove residues of AgCl. Finally they were
diluted to obtain the working solutions of [Pt(NH3)2(-
H2O)2](NO3)2 (PtII–H2O) and [Pt(NH3)2(-
H2O)2(OH)(O2CCH2CH2CO2H)](NO3)2 (PtIVsuc-H2O). Accurate
determination of the concentration of working solutions was
carried out by ICP-MS analysis.
Synthesis of 1-amino-5-(1,8-dimercapto-3,6-dioxaoctanyl)-
anthracene-9,10-dione (AA)
A similar procedure to that described for the non-amino
anthraquinone analog was followed.70 1-Amino-5-
chloroanthraquinone (1.43 g, 5 mmol) and 2,20-(ethylenedioxy)
diethanethiol (1.92 g, 10 mmol) were mixed with NaH (60% oil
dispersion, 0.80 g, 20 mmol) in anhydrous THF (100 mL), and
the mixture was stirred for 3 h at room temperature under
argon. The mixture was poured into ice-water (200 mL), and
acidied carefully to pH 5 by adding HCl 1 M. The solution was
extracted with CH2Cl2 (4  50 mL), the organic solution was
washed with water (2 50 mL) and dried over sodium sulphate.
The solvent was evaporated at reduced pressure, and the dark-
red residue was puried by column chromatography (silica
gel, CH2Cl2: ethyl acetate, 98 : 2, v/v). Rf 0.3. Yield 50%.
1H NMR
d, ppm (CDCl3): 3.88 (t, e5, 2H, J ¼ 6.9 Hz), 3.68 (m, e2/e3/e4,
6H), 3.27 (t, e6, 2H, J ¼ 6.96 Hz), 2.73 (dd, e1, 2H, J1 ¼
8.22 Hz, J2¼ 6.45 Hz), 1.62 (t, 1H, SH, J¼ 8.19), 6.84 (NH2), 6.96
(dd, a2, 1H, J¼ 8.34 Hz, J¼ 1.11 Hz), 7.50 (t, a3, 1H, J¼ 7.88 Hz),
7.67–7.70 (m, a4/a7/a8, 3H), 8.15 (dd, a6, 1H, J1 ¼ 6.00 Hz, J2 ¼
2.88 Hz). 13C NMR d, ppm (CDCl3): 135.0 (a3), 132.9 (a7), 128.8
(a8), 123.1 (a6), 122.3 (a2), 117.5 (a4), 73.0 (e2), 70.6, 70.2 (e3,
e4), 69.1 (e5), 31.6 (e6), 24.3 (e1). See 1H NMR and 13C NMR
spectra in Fig. S1.†
ESI-MS(+), m/z: 426.3 (M + Na)+. IR (cm1): 3460 (O–H), 3344
(S–H), 2890 m (N–H). The compound AA is soluble in acetone,
ethanol, methanol, CHCl3, CH2Cl2, THF and DMSO, but it is not
soluble in water. 3 (480 nm, ethanol) 9100 M1 cm1. Lumi-
nescence in ethanol: lexc 480 nm, lem 590 nm.
Preparation of GNP-lip
A modied protocol from that previously described by Lin et al.
was followed.71 A volume of 80 mL of NaOH 1 M was added to
16 mL of 14 nm-citrate GNPs and 1–2 min later, 1.6 mL of an
ethanolic solution of ()-a-lipoic acid (10 mM) was added. The
mixture was stirred at room temperature for 4 h in darkness. The
solution was further puried by centrifugation at 13000 rpm for
30 min. Supernatants were discarded and the pellets were re-
suspended in Milli-Q® water. Finally 108 mL of NaOH 1 M
were added to stabilize the suspension. Final concentration
(ICP-MS): 6 nM. IR (cm1): 1690 m (C]O), 1456 s.
Preparation of GNP-lip-AA
Direct functionalization of citrate GNPs with AA ligand was
attempted but, the resulting particles aggregated spontane-
ously, probably due to the absence of electric surface charge.
Therefore, stable negatively-charged GNP-lip particles were
partially substituted with AA to yield stable and negatively-
charged nanoparticles with a mixed surface.This journal is © The Royal Society of Chemistry 2019
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
A
ug
us
t 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
21
/2
01
9 
12
:4
0:
13
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online25 mL of 400 mM AA ethanolic solution was added to 100 mL
of a GNP-lip solution (3 nM) and stirred overnight (18 h) in
darkness and at room temperature, followed by washing with
chloroform until the washing solution was colorless. The
remaining chloroform was removed by rotary evaporation.
The solution was dialyzed (Spectra-Por® Float-A-Lyzer® G2, 5
mL, MWCO 8–10 kDa) for 2 days in deionized water with NaOH
1 M (0.5 mL/2 L) pH 10–11 and water changed every 6–8 hours.
The solution was ltered and stored at 4 C in the dark. The
absence of unbound AA is proved by the narrowing of the SPR
band and its shi to 528 nm (disappearance of the convoluted
band at 480 nm). Also, the band intensity around 240 nm
decreases signicantly. To ensure the absence of non-covalently
bound AA, periodic washings with chloroform were performed
and checked by UV-vis. Final concentration (ICP-MS): 2.5 nM.
To stabilize the colloidal suspension, NaOH 1 M was added
until pHz 11. IR (cm1): 1685 s (C]O, anthraq), 1639 s (C]O,
lip), 1420 m, 1055–1274 m, (aromatic C]C, C]N, anthraq)
(Fig. S8†). Luminescence in water: lexc 470 nm, lem 645 nm.
GNP-lip and GNP-lip-AA are both stable against precipitation in
water over a period of at least 3 months at 4 C.Attachment of platinum complexes to gold nanoparticles
To attach either PtII–H2O or PtIVsuc-H2O, the corresponding
aqueous platinum solution (4.8 mM for PtII–H2O, 3.7 mM for
PtIVsuc-H2O) was added slowly to the particle solution (3 nM for
GNP-lip, 2.5 nM for GNP-lip-AA) in the following molar ratios
GNP:Pt: 1 : 13  103 (GNP-lip-PtII), 1 : 10  103 (GNP-lip-
PtIVsuc), 1 : 6  103 (GNP-lip-AA-PtII), 1 : 4.5  103 (GNP-lip-
AA-PtIVsuc). In each case, the mixture was brought to pH 10.3
with NaOH 1 M and stirred overnight in darkness for 18 h.
Then, the solution was ltered and puried by centrifugation at
5000g for 30 min and further re-dispersed in NaOH 25 mM (pH
8.5). The selection of 5000g was made experimentally as higher
speeds led to problems with redispersion. Adding further
centrifugation steps, or brief (<2 h) dialyses in 25 mM NaOH,
didn't aﬀect loading as assessed by ICPMS.Drug release studies
Release studies in physiological media. Freshly-prepared and
puried Pt-functionalized nanoparticle suspensions (NaOH 25
mM, pH 8.5) were centrifuged at 5000g for 30 min and the pellets
re-dispersed in supplemented RPMI-1640 or DMEM cell media
(purchased by Gibco). The suspensions were incubated at 37 C
in darkness. Sample aliquots were taken over time and centri-
fuged to remove the supernatants containing the released drug.
Pellets were re-dissolved in clean cell media and digested (see
below) for ICP-MS analysis.
Both platinum and gold concentrations were determined
simultaneously. Cumulative release percentage was obtained
according to the following formula:
% released drug ¼

n0  nt
n0

 100
where n0 is the initial number of platinum atoms (from the
drug) per particle and nt is the number of platinum atoms atThis journal is © The Royal Society of Chemistry 2019a certain time interval. Two independent measurements were
carried out.
pH-dependent release studies
Freshly prepared and puried Pt-functionalized nanoparticle
suspensions (NaOH 25 mM, pH 8.5) were centrifuged at 5000g for
30 min and the pellets re-dispersed in phosphate buﬀer saline
(pH 7.4), or in phthalate buﬀer (pH 4.4). The solutions were kept
at room temperature and darkness. Aliquots were collected aer
3 h and 24 h, immediately centrifuged and resulting pellets were
re-dispersed in clean buﬀers. Gold and platinum concentrations
were determined simultaneously by ICP-MS. The percentage of
released drug was obtained in the sameway as that used to obtain
the cumulative release in cell media (vide supra).
Two independent measurements were carried out.
Phthalate buﬀer pH 4.4 was prepared by adding 20 mL of
0.1 M NaOH to 100 mL 0.1 M potassium hydrogen phthalate.
ICP-MS analysis
Samples were digested with aqua regia at 80 C overnight, then
diluted to 2% aqua regia solutions and ltered. Platinum and
gold standards (Fluka) were prepared containing 2% aqua regia.
Gold and platinum (195Pt) concentrations were simulta-
neously determined in an Agilent 7500CX ICP-MS (Pt simple
cone in no-gas mode). Analysis conditions: Ar ow: 15 L min1,
auxiliar gas 0.9 L min1, make-up gas 0.15 L min1, RF power
1550 W, RF matching 1.8 V, analog HV 1750 V, Pulse HV 1130 V,
spray chamber temperature 15 C, nebuliser pump 0.08 rps.
Internal standard (50 ppb Er solution) is introduced into the
sample ow through a T-piece. All readings were in triplicate.
Results are means  s.d. of three independent experiments.
Concentration of gold measured by ICP-MS combined with
the known size of particles from TEM characterization allows
calculation of particle concentration.
Cell culture
Human ovarian carcinoma A2780 and human lung carcinoma
A549 cell lines were obtained from The European Collection of
Authenticated Cell Cultures (ECACC) operated by Public Health
England (A549 cat number 86012804; A2780 cat number
93112519) and maintained in Roswell Park Memorial Institute
medium (RPMI-1640) (GE Healthcare) and Dulbecco's Modied
Eagle Medium (DMEM) (Gibco), respectively, in both cases
supplemented with FBS (10%, v/v), penicillin (50 U mL1
culture medium), streptomycin (50 mg mL1 culture medium)
and L-glutamine (2 mM). Cells were grown in a humidied
incubator at 37 C, 5% CO2, and 95% relative humidity. Cells
were routinely sub cultured using a 1 in 4 dilution using
a standard trypsin–EDTA protocol.
MTT cell proliferation assay
Human A2780 and A549 cells at logarithmic growth phase (6 
104 and 5 104 cells per mL, respectively) were added to 96-well
culture plates, respectively, at 100 mL per well, and incubated
overnight to allow attachment.Chem. Sci., 2019, 10, 9244–9256 | 9253
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View Article OnlineMedium was removed and replaced with 100 mL of medium
containing sample at diﬀerent concentrations (four replicates
per sample), and the plates were incubated at 37 C in 5% CO2,
95% relative humidity for 72 hours. Cells were thoroughly
washed with PBS before adding 100 mL of thiazolyl blue tetra-
zolium bromide (0.5 mgmL1). The cells were further incubated
for 2 h. The media was carefully removed by aspiration and 200
mL of DMSO added to dissolve the purple crystals. Absorbance
was measured using a 96-well plate reader set at 590 nm. Non-
treated cells were used as a control. Results are the mean 
SD of at least three independent experiments. Concentration of
GNP and platinum of assayed sample solutions were accurately
determined by ICP-MS. Light microscopies and TEM images
indicated cell death and not just cytostasis.
Confocal Microscopy
A2780 and A549 cells were seeded in 6-well plates onto sterilised
circular glass slides of 2 cm diameter at 40% conuence and le
incubating overnight to attach. Next day, cells were washed with
PBS, treated with 0.6 nM solutions of nanoparticles and further
incubated at 37 C for 3 h and 24 h. For the last 30 min of each
incubation period, cells were treated with Hoechst 33258 at
a nal concentration of 4 mM for nucleus-staining and le
incubating at 37 C. Then cells were washed with PBS and xed
with 4% paraformaldehyde for 15min, followed by washing with
PBS (2) to remove paraformaldehyde. Coverslips weremounted
onto microscope slides using non-uorescent aqueous Hydro-
mount (National Diagnostics, UK) as mounting solution.
Samples were imaged on a Leica SP2-AOBS Inverted Confocal
Laser ScanningMicroscope with an oil immersion objective HCX
PL APO lbd.BL 63.0  1.40 OI. Fluorescence images were taken
using the laser lines 405 nm (Hoechst) and 458-476-488–496 nm
(GNP-lip-AA). For transmission and reection images, 405 nm
and 488 nm laser lines were used respectively. Images were
processed by ImageJ soware (http://rsbweb.nih.gov/ij/).
Transmission electron microscopy
For characterization of nanoparticles, a JEOL2100 TEM, 200 keV
and Gatan multiscan camera was used. Cell uptake samples (24
h) were imaged using JEOL1200EX TEM, 80 keV and Gatan
multiscan camera. Cells were seeded in 6-well plates onto
sterilised circular glass coverslips of 1 cm diameter at 30%
conuency and le incubating overnight to attach. Next day,
cells were washed with PBS, treated with 0.6 nM solutions of
nanoparticles and further incubated for 24 h. Aerwards the
slides were washed with PBS and submerged in glutaraldehyde/
formaldehyde (2.5%, 0.5 M PBS). Cells were subsequently
placed in 1% osmium tetroxide solution and gradually dehy-
drated with alcohol and propylene oxide. Then they were
embedded in resin and ultrathin sections (50–150 nm) obtained
which were mounted onto copper electron microscope grids
(Formvar lm). Samples were contrasted with uranyl acetate
and lead citrate.
TEM images were acquired using Digital Micrograph 1.8
(Gatan, CA, USA) and post-imaging analysis was performed
using ImageJ.9254 | Chem. Sci., 2019, 10, 9244–9256DNA-binding studies
Both CD and LD titration were performed by adding increasing
concentration of compound (GNP and AA from stock solutions
in water and ethanol respectively) to calf thymus (ct) DNA (75
mM in NaCl 10 mM and Tris HCl 1 mM pH 7.5). Equal volume of
ct-DNA 150 mM was added at each addition of compound, to
keep DNA concentration constant. ct-DNA (supplied by Sigma-
Aldrich) concentration was determined by UV-vis using the
molar extinction coeﬃcient 3258 ¼ 6600 M1 cm1.
CD spectra were recorded at 20 C on a Jasco J-810 spec-
tropolarimeter whilst LD experiments were performed using
a Chirascan-plus instrument by Applied Photophysics provided
of the High Shear Couette Cell Accessory (CCA).
All dynamic light scattering (DLS) measurements were per-
formed using a Malvern Zetasizer Nano ZSP, using a 4 mW He–
Ne laser with an operating wavelength of 633 nm. For size
measurements, temperature was maintained at 25 C with an
equilibration times of 120 before a measurement was per-
formed. 3 min equilibration was allowed aer each GNP addi-
tion and before recording a measurement. Disposable cuvettes
(DTS0012) were used for all measurements, with 5 measure-
ments per run, with a 173 backscatter measuring angle and
avalanche photodiode detector employed. Data presented is the
mean of 5 measurements.Atomic Force Microscopy
Atomic Force Microscopy was performed on a Keysight N9418S
9500 Atomic Force Microscope in a tapping mode at room
temperature (25 C and 60% humidity) using Hi'Res-C15/Cr–
Au probes (Apex Probes Ltd; 325 kHz resonance frequency, 40 N
m1 force constant). AFM images had a resolution of 512  512
px and were scanned with a speed of 1.5 lines per s. Surfaces
were prepared by treating freshly cleaved mica with nickel(II)
chloride solution (40 mL, 100 mM; 20 min) washing with Milli-Q
water and drying under nitrogen. Linearized pBR-322 plasmid
DNA was prepared by incubation with Pst1-HF restriction
enzyme (New England BioLabs) for 1 h at 37 C, and puried
using a QAIquick PCR purication column eluted with Milli-Q
water. Its concentration was determined using a NanoDrop
8000 UV-vis spectrometer, and cleavage conrmed by Agarose
Gel Electrophoresis.
23 mL of 6 nMGNP-lip-AA was added to an Eppendorf, followed
by 153 mL of Milli-Q water. To this, 4 mL of 54.2 mM (in base pairs)
linearized pBR-322 plasmid DNA was added and mixed before
addition of 20 mL of 10 buﬀer (100 mM NaCl, 10 mM Tris-base).
The nal ratio was two NP's per linearized pBR-322 molecule
(4361bp). DNA alone solution was prepared using 23 mL of Milli-Q
water instead of the NP solution. Nanoparticle-DNA solution (40
mL) was pipetted onto the Nickel treated mica surface and le to
incubate for 70 minutes. This was then washed with 500 mL of
Milli-Q water and dried under nitrogen.Conclusions
We have shown that lipoic-gold nanoparticles (GNP) can be
eﬀective delivery platforms for Pt(II) and Pt(IV) metallodrugs,This journal is © The Royal Society of Chemistry 2019
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View Article Onlinetransporting them into cells. The synthetic strategy we have
employed allows rapid preparation of the GNP-drug conjugates,
with enhanced loading of the drug on the surface of the nano-
carriers, compared to other strategies reported so far with
similar systems.{ The drug is released in a pH-dependent
fashion, with the highest level of release at lower pH. This is
a potential advantage considering the acidic microenvironment
that is associated with many tumor cells in vivo. The simple
GNP-lip carrier particularly enhanced the eﬃcacy of the plati-
num(IV) agents against lung A549 and ovarian A2780 tumor cells
in culture.
Because the nanocarriers can also carry a uorescent tag,
these conjugates can also represent a system with a multimodal
capability (drug delivery and imaging). The design has delib-
erately used a non-inert uorescent tag that also plays a second
(DNA-binding) role, though it should be possible in future
designs to separate those functions into two molecular
components allowing the uorescence and cytotoxic activity to
be separately modulated if desired. The nanoparticles and their
conjugates, enter cells within 3 hours. They tend to cluster in
vesicles (and this probably reects their mechanism of uptake)
but can escape and are seen in the cytoplasm, endoplasmic
reticulum and nucleus.
Crucially, the introduction of the aminoanthraquinone (AA)-
based uorophore leads to enhanced toxicity of the gold nano-
carrier, demonstrating that we can create nanocarriers that are is
not just inert components, with a role just to deliver and release
the drug; this opens new thinking in how a nanoparticle might
be used not only as a drug carrier, and not only to carry both
therapy and imaging agents, but to itself contribute to
enhancing the cytotoxic action. The activity levels of the nano-
carrier GNP-lip-AA were surprisingly high, and indeed may need
to be modulated to suit the choice of drugs being delivered.
Excitingly we have shown that these AA functionalised
nanoparticles (GNP-lip-AA) cause remarkable coiling/wrapping
of DNA despite their anionic surface charge. This is an unex-
pected and very interesting new aspect of DNA binding since
such an eﬀect is more commonly associated with polycations.
Given that cationic nanoparticles can disrupt membranes in the
cell,33,34 anionic nanoparticles that can cause such dramatic
eﬀects on DNA may have fascinating potential for new
approaches to in-cell nucleic acid recognition.Conﬂicts of interest
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